How to buy Halozyme Therapeutics stock (HALO)

Halozyme Therapeutics is a biotechnology business based in the US. Halozyme Therapeutics shares (HALO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $47.54 – an increase of 0.46% over the previous week. Halozyme Therapeutics employs 373 staff and has a trailing 12-month revenue of around $947.4 million.

Our top picks for where to buy Halozyme Therapeutics stock

Buy Halozyme Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Halozyme Therapeutics stock price (NASDAQ: HALO)

Use our graph to track the performance of HALO stocks over time.

Halozyme Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$47.54
52-week range	$33.15 - $65.53
50-day moving average more info button	$51.31
200-day moving average more info button	$50.11
Wall St. target price	$64.00
PE ratio more info button	15.5099
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$3.02

Is it a good time to buy Halozyme Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Halozyme Therapeutics price performance over time

Historical closes compared with the close of $47.54 from 2024-12-24

1 week (2024-12-19)	0.46%
1 month (2024-11-26)	-0.52%
3 months (2024-09-26)	-16.52%
6 months (2024-06-26)	-8.58%

1 year (2023-12-26)	27.21%
2 years (2022-12-23)	-17.31%
3 years (2021-12-23)	18.14%
5 years (2019-12-26)	159.92%

Is Halozyme Therapeutics stock undervalued or overvalued?

Valuing Halozyme Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Halozyme Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Halozyme Therapeutics's P/E ratio

Halozyme Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Halozyme Therapeutics shares trade at around 16x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Halozyme Therapeutics's EBITDA

Halozyme Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $553 million.

The EBITDA is a measure of a Halozyme Therapeutics's overall financial performance and is widely used to measure a its profitability.

Halozyme Therapeutics financials

Revenue TTM	$947.4 million
Operating margin TTM	56.26%
Gross profit TTM	$454.2 million
Return on assets TTM	14.87%
Return on equity TTM	111.83%
Profit margin	41.43%
Book value	$3.56
Market Capitalization more info button	$6 billion

TTM: trailing 12 months

Halozyme Therapeutics share dividends

We're not expecting Halozyme Therapeutics to pay a dividend over the next 12 months.

Have Halozyme Therapeutics's shares ever split?

Halozyme Therapeutics's shares were split on a 171:40 basis on 9 December 2003 . So if you had owned 40 shares the day before before the split, the next day you'd have owned 171 shares. This wouldn't directly have changed the overall worth of your Halozyme Therapeutics shares – just the quantity. However, indirectly, the new 76.6% lower share price could have impacted the market appetite for Halozyme Therapeutics shares which in turn could have impacted Halozyme Therapeutics's share price.

Halozyme Therapeutics share price volatility

Over the last 12 months, Halozyme Therapeutics's shares have ranged in value from as little as $33.15 up to $65.5327. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Halozyme Therapeutics's is 1.29. This would suggest that Halozyme Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Halozyme Therapeutics overview

Halozyme Therapeutics, Inc. , a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy.

Frequently asked questions

null
What percentage of Halozyme Therapeutics is owned by insiders or institutions?
Currently 1.063% of Halozyme Therapeutics shares are held by insiders and 100.828% by institutions. How many people work for Halozyme Therapeutics?
Latest data suggests 373 work at Halozyme Therapeutics. When does the fiscal year end for Halozyme Therapeutics?
Halozyme Therapeutics's fiscal year ends in December. Where is Halozyme Therapeutics based?
Halozyme Therapeutics's address is: 12390 El Camino Real, San Diego, CA, United States, 92130 What is Halozyme Therapeutics's ISIN number?
Halozyme Therapeutics's international securities identification number is: US40637H1095 What is Halozyme Therapeutics's CUSIP number?
Halozyme Therapeutics's Committee on Uniform Securities Identification Procedures number is: 40637H109